• Gepotidacin Pharmacokinetics in Phase I Studies

  2026-09-02

  This reference paper characterizes the pharmacokinetics, safety, and tolerability of gepotidacin, also known as GSK2140944, across single- and repeat-dose studies in healthy adults and elderly participants. Its findings define dose exposure, time to steady state, food effects, and early tolerability for a first-in-class antibacterial agent with a distinct bacterial topoisomerase pathway.

• ML216: BLM Helicase Inhibitor Workflows

  2026-09-01

  ML216 enables mechanism-focused studies of BLM-dependent DNA repair, from biochemical helicase assays to sister chromatid exchange and cell proliferation experiments. Its selective cellular phenotype also supports controlled studies of chemotherapy sensitization and RecQ-helicase vulnerabilities, provided BLM and WRN interpretations are kept distinct.

• HOXC8, Caspase-1, and Pyroptosis in NSCLC

  2026-09-01

  The 2025 Cell Death and Disease study shows that HOXC8 supports non-small cell lung cancer by repressing CASP1 transcription and preventing caspase-1-dependent pyroptosis. Its central mechanistic advance is the identification of an HOXC8–HDAC1/2 regulatory complex at the CASP1 promoter, linking a developmental transcription factor to inflammatory cell death and tumor growth.

• DDM for Cryo-EM Integrin Sample Quality

  2026-08-31

  n-Dodecyl-β-D-maltoside (DDM) is more than a membrane protein solubilization detergent: its micelle behavior can shape conformational and surface-dependent assay outcomes. This guide connects DDM selection with recent full-length αvβ3 cryo-EM insights and practical sample decisions.

• HRP Rabbit Anti-Goat IgG (H+L) Antibody Workflow

  2026-08-30

  Build sensitive, reproducible assays for goat primary antibodies across western blotting, ELISA, dot blotting, and tissue staining. This workflow connects practical HRP optimization with pulmonary fibrosis research on microplastics and nanoplastics while separating study-derived parameters from assay recommendations.

• Nullscript in Reliable Cell Assay Design

  2026-08-29

  This scenario-based guide explains how Nullscript (SKU C3606) can support controlled HDAC-mechanism studies alongside cell viability, proliferation, and cytotoxicity assays. It emphasizes formulation checks, assay compatibility, interpretation limits, and evidence-based selection of a research-grade histone deacetylase inhibitor.

• Okadaic acid (A4540): PP1/PP2A Assay Guide

  2026-08-29

  Okadaic acid (A4540) provides controlled inhibition of PP2A and PP1 for phosphorylation-dependent signaling, phosphatase assays, and selected apoptosis workflows. This guide explains stock handling, assay controls, endpoint selection, and interpretation limits; it should not be treated as a broad-spectrum phosphatase or universally validated apoptosis reagent.

• Neticonazole Hydrochloride: Mechanisms & Uses

  2026-08-28

  Neticonazole Hydrochloride is an imidazole antifungal used topically for superficial cutaneous candidiasis. Product information also describes preclinical colorectal cancer research involving exosome inhibition and apoptosis induction via Bcl-2/Bax regulation, but these oncology findings do not establish a human cancer treatment.

• iPSC Organoids Reveal Pan-Tissue HEV Infection

  2026-08-28

  This study establishes induced pluripotent stem cell-derived liver, intestinal and brain organoids as multilineage models that sustain complete propagation of wild-type hepatitis E virus genotypes 1, 3 and 4. The findings map previously under-resolved cellular tropism and tissue injury across the liver–intestine–brain axis, while demonstrating the platform’s value for host–pathogen research and antiviral evaluation.

• PF-562271 HCl: FAK/Pyk2 Workflow

  2026-08-27

  PF-562271 HCl provides a reversible, ATP-competitive way to interrogate FAK/Pyk2 signaling across adhesion, migration, survival, and tumor models. This workflow connects target engagement with the metabolic and therapy-resistance insights reported in ER-HER2-positive breast cancer research, while clearly separating established evidence from testable extensions.

• How Mycobacterium tuberculosis WecA Was Characterized

  2026-08-27

  The reference study establishes an experimentally tractable workflow for producing, purifying, identifying, and kinetically analyzing the difficult 11-transmembrane Mycobacterium tuberculosis enzyme WecA. Its UMP-based activity assay and evidence that tunicamycin acts competitively provide a practical foundation for mechanistic studies and inhibitor discovery.

• PEP, cGAS–STING, and Healthy Aging

  2026-08-26

  The reference study identifies phosphoenolpyruvate (PEP) as an adaptive glycolytic metabolite that restrains cGAS-driven inflammation and supports healthy aging. Its combination of longitudinal profiling, metabolic perturbation, mechanistic binding studies, and an Alzheimer’s disease model provides a framework for connecting central carbon metabolism with inflammaging.

• Gepotidacin in UTI: EAGLE-2 and EAGLE-3

  2026-08-26

  The phase 3 EAGLE-2 and EAGLE-3 trials evaluated oral Gepotidacin (GSK2140944), a first-in-class triazaacenaphthylene antibiotic, against nitrofurantoin for uncomplicated urinary tract infection. Gepotidacin was non-inferior in both trials and superior in EAGLE-3, supporting further investigation of bacterial topoisomerase inhibition as an approach to antibiotic resistance research.

• Nanoparticle mRNA Delivery Reverses Trastuzumab Resistance

  2026-08-25

  Dong and colleagues developed a tumor-microenvironment-responsive nanoparticle system for systemic delivery of PTEN mRNA in trastuzumab-resistant HER2-positive breast cancer. Their findings support a mechanistic strategy in which restoring PTEN expression suppresses compensatory PI3K/Akt signaling and improves the response to trastuzumab.

• FerroOrange for Live-Cell Fe²⁺ Detection

  2026-08-25

  FerroOrange converts intracellular ferrous-ion availability into a measurable fluorescence increase for live-cell microscopy, flow cytometry, and plate-based assays. This workflow-oriented guide shows how to apply it to ferroptosis and ischemic-stroke models while avoiding common errors involving dead cells, irreversible signal accumulation, and inconsistent acquisition.

452 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page